{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001465","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.589060+00:00","generated_at":"2026-06-05T19:57:14.138449+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M","bullets":["WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).","GAAP diluted EPS $0.45 vs $0.79 YoY; non-GAAP adjusted EPS $0.73 vs $1.01.","FDA granted priority review for WAKIX in pediatric narcolepsy; PDUFA June 21, 2024.","2024 net product revenue guidance $700-720M, up from ~$582M in 2023.","Repurchased 3.2M shares for $100M in 2023; $150M remaining authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001465","json":"https://secwatch.observer/filing/0001558370-24-001465.json","markdown":"https://secwatch.observer/filing/0001558370-24-001465.md","text":"https://secwatch.observer/filing/0001558370-24-001465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/0001558370-24-001465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/hrmy-20240222x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:57:14.138449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9de821dbcdea39d0245c195a7cfd97a84a48b673","claim":"Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/0001558370-24-001465-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}